Commodore Capital LP Q1 2022 Filing
Filed May 16, 2022
Portfolio Value
$447.7B
Holdings
27
Report Date
Q1 2022
Filing Type
13F-HR
All Holdings (27 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | MRUSMERUS N V | 1,816,421 | $48.0B | 10.73% | |
| 2 | ACRSACLARIS THERAPEUTICS INC | 2,314,648 | $39.9B | 8.91% | |
| 3 | BLUBELLUS HEALTH INC NEW | 5,637,630 | $38.8B | 8.66% | |
| 4 | OPHTEURIVERIC BIO INC | 2,214,961 | $37.3B | 8.33% | |
| 5 | XENEXENON PHARMACEUTICALS INC | 1,202,613 | $36.8B | 8.21% | |
| 6 | CYTKCYTOKINETICS INC | 854,652 | $31.5B | 7.03% | |
| 7 | KPTIEURKARYOPHARM THERAPEUTICS INC | 3,561,052 | $26.2B | 5.86% | |
| 8 | COGTCOGENT BIOSCIENCES INC | 3,500,768 | $26.2B | 5.86% | |
| 9 | CBAYUSDCYMABAY THERAPEUTICS INC | 5,738,500 | $17.8B | 3.99% | |
| 10 | VRDNVIRIDIAN THERAPEUTICS INC | 951,339 | $17.6B | 3.93% | |
| 11 | 1T7TRICIDA INC | 1,744,570 | $14.3B | 3.20% | |
| 12 | —SATSUMA PHARMACEUTICALS INC | 3,711,286 | $14.1B | 3.15% | |
| 13 | VTGNUSDVISTAGEN THERAPEUTICS INC | 10,097,229 | $12.5B | 2.80% | |
| 14 | KURAKURA ONCOLOGY INC | 776,514 | $12.5B | 2.79% | |
| 15 | CCCCC4 THERAPEUTICS INC | 481,094 | $11.7B | 2.61% | |
| 16 | IMUXIMMUNIC INC | 893,013 | $10.1B | 2.25% | |
| 17 | CELCCELCUITY INC | 920,464 | $8.6B | 1.92% | |
| 18 | TCE2CELLDEX THERAPEUTICS INC NEW | 241,199 | $8.2B | 1.83% | |
| 19 | PTGXPROTAGONIST THERAPEUTICS INC | 331,886 | $7.9B | 1.76% | |
| 20 | TNYATENAYA THERAPEUTICS INC | 513,930 | $6.1B | 1.35% | |
| 21 | KALVKALVISTA PHARMACEUTICALS INC | 312,553 | $4.6B | 1.03% | |
| 22 | GNCAQGENOCEA BIOSCIENCES INC | 3,079,756 | $3.9B | 0.86% | |
| 23 | IVAINVENTIVA SA | 262,658 | $3.0B | 0.67% | |
| 24 | DYNDYNE THERAPEUTICS INC | 305,125 | $2.9B | 0.66% | |
| 25 | PMVPPMV PHARMACEUTICALS INC | 125,000 | $2.6B | 0.58% | |
| 26 | —BCLS ACQUISITION CORP | 250,000 | $2.5B | 0.55% | |
| 27 | MREOMEREO BIOPHARMA GROUP PLC | 1,954,970 | $2.2B | 0.49% |